Percutaneous Ultrasound Gastrostomy: Clinical Evaluation of a Feeding Tube Placement Method in the Pediatric Population

Information

  • Research Project
  • 10268249
  • ApplicationId
    10268249
  • Core Project Number
    R44DK123910
  • Full Project Number
    5R44DK123910-03
  • Serial Number
    123910
  • FOA Number
    PA-19-273
  • Sub Project Id
  • Project Start Date
    9/20/2019 - 5 years ago
  • Project End Date
    8/31/2022 - 2 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    9/1/2021 - 3 years ago
Organizations

Percutaneous Ultrasound Gastrostomy: Clinical Evaluation of a Feeding Tube Placement Method in the Pediatric Population

The percutaneous ultrasound gastrostomy (PUG) method has been made possible using the PUMA-G System. The PUMA-G System was successfully developed by CoapTech, LLC with SBIR Phase I support (R43 DK115325) leading to FDA 510(k) clearance for use in adults in April 2019. As of May 1, 2020, the PUMA-G adult device has been used for G-tube placement in over 90 patients at more than half a dozen medical centers in the US and Canada with no device- related adverse events. Strong demand from clinicians has led the company to pursue a pediatric application of the system to enable safe, ultrasound guided gastrostomy tube placement for children. In collaboration with expert pediatric proceduralists from three premier pediatric academic medical centers, and via funding from the NIH?s SBIR program (R43DK12391), CoapTech made extensive advances to its original design in order to meet the unique clinical needs of pediatric patients, including infants (<10kg) and children (10-30kg). Successful engineering of the Pediatric PUMA-G System was confirmed in benchtop and animal models. The proposed SBIR Phase II research project will advance the prototype sized for children through phases of production into a medical grade device in order to evaluate its safety and efficacy at three major, pediatric academic medical centers: Children?s Hospital of Philadelphia, Children?s National Hospital, and Columbia New York Presbyterian Hospital. Assuming successful results, the company would be able to use data gleaned in applications to FDA, and to aid in marketing the Pediatric PUMA-G System to physicians with initial supporting data of relative safety, cost advantages, time savings, and to accelerate development of an infant PUMA-G System.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    774058
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:774058\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    COAPTECH, LLC
  • Organization Department
  • Organization DUNS
    080322442
  • Organization City
    BALTIMORE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    212024268
  • Organization District
    UNITED STATES